← Leaderboards
Donald N Forthal
University Of California Irvine
$14,427,891
Attributed
$16,568,248
Total exposure
19
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,568,248 · 19
By mechanism
R01$9,056,338 · 4
U54$3,276,287 · 2
R21$2,354,277 · 5
R33$1,196,849 · 1
M01$534,097 · 6
R03$150,400 · 1
Top collaborators
- Ellena Marie Peterson5 shared
- Christopher Miller4 shared
Most similar at University Of California Irvine
Same institution · by research overlap
- Shannon N Bennett$2,400,085
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsInfectionIn VitroVaccinesVirusMediatingAntibodiesCellsDesignTissuesVaccinationLeadHiv-1PreventBaseLaboratoriesImmunoglobulin GMacacaIn VivoBinding (Molecular Function)Research PersonnelNovel StrategiesAntigen-Antibody ComplexPlay
Grant awards (53)
Nucleic acid-containing immune complexes and immune activation$196,250
R21 · FY2025 · AI · contact PI
Nucleic acid-containing immune complexes and immune activation$211,950
R21 · FY2024 · AI · contact PI
The Fc neonatal receptor and antibody-dependent enhancement of dengue virus infection$203,290
R21 · FY2021 · AI · contact PI
The Fc neonatal receptor and antibody-dependent enhancement of dengue virus infection$262,948
R21 · FY2020 · AI · contact PI
The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection$531,993
R01 · FY2019 · AI · contact PI
The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection$531,993
R01 · FY2018 · AI · contact PI
The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection$531,993
R01 · FY2017 · AI · contact PI
The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection$737,266
R01 · FY2016 · AI · contact PI
The impact of antibody and pH on female-to-male SIV infection$663,075
R01 · FY2015 · AI · contact PI
The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection$545,573
R01 · FY2015 · AI · contact PI
The impact of antibody and pH on female-to-male SIV infection$682,866
R01 · FY2014 · AI · contact PI
PSWRCE Cpmprehensive Program Training Program for High Containment Lab$682,862
U54 · FY2013 · AI · contact PI
The impact of antibody and pH on female-to-male SIV infection$641,194
R01 · FY2013 · AI · contact PI
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens$447,247
R01 · FY2013 · AI · contact PI
Iron Starvation: A novel strategy for HIV and Chlamydia microbicides$391,078
R33 · FY2013 · AI
Rodent Animal Biosafety Level 3 (ABSL3)$65,525
U54 · FY2013 · AI · contact PI
The impact of antibody and pH on female-to-male SIV infection$682,061
R01 · FY2012 · AI · contact PI
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens$492,717
R01 · FY2012 · AI · contact PI
PSWRCE Cpmprehensive Program Training Program for High Containment Lab$472,678
U54 · FY2012 · AI · contact PI
Iron Starvation: A novel strategy for HIV and Chlamydia microbicides$387,446
R33 · FY2012 · AI
Rodent Animal Biosafety Level 3 (ABSL3)$120,393
U54 · FY2012 · AI · contact PI
PSWRCE Cpmprehensive Program Training Program for High Containment Lab$660,904
U54 · FY2011 · AI · contact PI
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens$518,081
R01 · FY2011 · AI · contact PI
Iron Starvation: A novel strategy for HIV and Chlamydia microbicides$418,325
R33 · FY2011 · AI
Rodent Animal Biosafety Level 3 (ABSL3)$103,655
U54 · FY2011 · AI · contact PI
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens$574,520
R01 · FY2010 · AI · contact PI
PSWRCE Cpmprehensive Program Training Program for High Containment Lab$477,595
U54 · FY2010 · AI · contact PI
Iron Starvation: A novel strategy for HIV and Chlamydia microbicides$206,487
R21 · FY2010 · AI
Rodent Animal Biosafety Level 3 (ABSL3)$98,259
U54 · FY2010 · AI · contact PI
CNTN$10,534
M01 · FY2010 · RR · contact PI
PSWRCE Cpmprehensive Program Training Program for High Containment Lab$492,208
U54 · FY2009 · AI · contact PI
Protective immunity against HIV: the role of IgG subclass and glycosylation$222,455
R21 · FY2009 · AI · contact PI
Iron Starvation: A novel strategy for HIV and Chlamydia microbicides$208,182
R21 · FY2009 · AI
Protective immunity against HIV: the role of IgG subclass and glycosylation$188,300
R21 · FY2009 · AI · contact PI
Rodent Animal Biosafety Level 3 (ABSL3)$102,208
U54 · FY2009 · AI · contact PI
CNTN$101,148
M01 · FY2009 · RR · contact PI
Protective immunity against HIV: the role of IgG subclass and glycosylation$239,250
R21 · FY2008 · AI · contact PI
Fcy Receptor Polymorphisms and Risk of HIV Infection$211,760
R21 · FY2008 · AI · contact PI
CNTN$140,762
M01 · FY2008 · RR · contact PI
Fcy Receptor Polymorphisms and Risk of HIV Infection$203,405
R21 · FY2007 · AI · contact PI
CNTN$93,657
M01 · FY2007 · RR · contact PI
CNTN$91,225
M01 · FY2006 · RR · contact PI
Novel Biological Activities of Anti-Viral Antibody$50,630
R01 · FY2006 · AI · contact PI
Novel Biological Activities of Anti-Viral Antibody$344,599
R01 · FY2005 · AI
CNTN$43,020
M01 · FY2005 · RR
Novel Biological Activities of Anti-Viral Antibody$372,690
R01 · FY2004 · AI
CNTN$41,359
M01 · FY2004 · RR
Protective Immunity against Breast Cancer$12,392
M01 · FY2004 · RR
Novel Biological Activities of Anti-Viral Antibody$374,660
R01 · FY2003 · AI
Novel Biological Activities of Anti-Viral Antibody$30,364
R01 · FY2003 · AI
Novel Biological Activities of Anti-Viral Antibody$302,816
R01 · FY2002 · AI
IMMUNOPROPHYLAXIS--DEFINING PROTECTIVE ANTIBODY FUNCTION$75,200
R03 · FY2001 · AI
IMMUNOPROPHYLAXIS--DEFINING PROTECTIVE ANTIBODY FUNCTION$75,200
R03 · FY2000 · AI